Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fast-TRKing Drug Development for Rare Molecular Targets.

Cancer discovery - 1 Sept 2017

Parikh Aparna R, Corcoran Ryan B

Abstract excerpt

<b/> Drug development for rare molecular targets in oncology presents unique challenges. In this issue of Cancer Discovery, Drilon and colleagues report the accelerated development and innovative initial clinical trial strategy of a next-generation TRK inhibitor, LOXO-195, designed to overcome common secondary TRK resistance mutations. Cancer Discov; 7(9); 934-6. ©2017 AACR.See related article by Drilon et al.,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28864638
DOI: 10.1158/2159-8290.CD-17-0704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fast-TRKing Drug Development for Rare Molecular Targets.PMID 28864638Read ↗

Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.Semantic proximity Read ↗

Revolutionizing cancer drug development: Harnessing the potential of basket trials.Semantic proximity Read ↗

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid TumorsSemantic proximity Read ↗

Larotrectinib for the treatment of TRK fusion solid tumorsSemantic proximity Read ↗

FGFR-TACC approaches the first turn in the race for targetable GBM mutations.Semantic proximity Read ↗

Targeting TRK: A Fast Tracked Application of Precision Oncology and Future DirectionsSemantic proximity Read ↗

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinibSemantic proximity Read ↗

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.Semantic proximity Read ↗

The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.Semantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

Drug pipeline: 1Q12.Semantic proximity Read ↗

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.